CardioDx Expands Patient Access to the Corus(R) CAD Test Through National Agreement With Quest Diagnostics
CardioDx Also Separately Raises $20 Million in New Financing to Support the Company's Commercial Growth and Operations
Redwood City, CA, September 16, 2015 – CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD)*.
Under a multi-year agreement, clinicians will be able to order blood draws on patients for testing through Quest's approximately 2,200 patient service centers and 4,000 phlebotomists in physician offices in the United States. Samples will be forwarded to CardioDx's CLIA-certified laboratory (in Redwood City, Calif.) for testing.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.